Literature DB >> 28149767

Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.

Chul Kim1, Arun Rajan1, Pedro A DeBrito2, Giuseppe Giaccone3.   

Abstract

In recent years, significant advances have been made in cancer immunotherapy. Here, we present the first report of a patient with lymphoepithelioma-like carcinoma (LELC) of the lung, an Epstein-Barr virus (EBV)-associated lung cancer, who was treated with nivolumab, a fully human IgG4 anti-PD-1 monoclonal antibody. We also carry out a focused review to identify and examine studies of LELC of the lung in the literature. This case report highlights the need to further assess the role of immune checkpoint inhibitors in LELC of the lung.

Entities:  

Keywords:  Lymphoepithelioma-like carcinoma of the lung (LELC of the lung); immunotherapy; nivolumab

Year:  2016        PMID： 28149767      PMCID： PMC5233874          DOI： 10.21037/tlcr.2016.11.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  39 in total

1.  Primary lymphoepithelioma-like carcinoma of the lung. A clinicopathologic study of 11 cases.

Authors:  J K Chan; P K Hui; W Y Tsang; C K Law; C C Ma; T T Yip; Y F Poon
Journal:  Cancer       Date:  1995-08-01       Impact factor: 6.860

2.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 4.  Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.

Authors:  Arun Rajan; Chul Kim; Christopher R Heery; Udayan Guha; James L Gulley
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

Review 5.  The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Authors:  Thomas F Gajewski
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

6.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

7.  Lack of epidermal growth factor receptor gene mutations in exons 19 and 21 in primary lymphoepithelioma-like carcinoma of the lung.

Authors:  Qianwen Liu; Guowei Ma; Haoxian Yang; Jing Wen; Mei Li; Hong Yang; Kongjia Luo; Yi Hu; Jianhua Fu
Journal:  Thorac Cancer       Date:  2014-01-02       Impact factor: 3.500

8.  Detection of rearrangement of anaplastic lymphoma kinase (ALK) and mutation of epidermal growth factor receptor (EGFR) in primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Liang Wang; Yongbin Lin; Qingqing Cai; Hao Long; Yu Zhang; Tiehua Rong; Guowei Ma; Ying Liang
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

Review 9.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
View more
  16 in total

1.  Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study.

Authors:  Hejing Bao; Ling Zhen Ma; Chengzhu Zhao; Mengge Yu; Baishen Zhang; Juan Zhang; Guibao Peng; Xiaotong Lin; Yinhua Fang; Hehong Bao; Shudong Ma
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-04       Impact factor: 4.553

Review 2.  Primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Ying Fan; Chenghui Li; Jing Qin; Hongyang Lu
Journal:  Med Oncol       Date:  2020-03-07       Impact factor: 3.064

3.  CD56+ lymphoepithelioma-like carcinoma of the lung: A case report and literature review.

Authors:  Lin Yang; Hua Liang; Li Liu; Lei Guo; Jian-Ming Ying; Su-Sheng Shi; Xing-Sheng Hu
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

4.  Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma.

Authors:  David J Hermel; Emma Z Du; Ray Lin; Catherine T Frenette; Darren S Sigal
Journal:  J Clin Transl Hepatol       Date:  2021-02-01

5.  High PD-L1 level of advanced hepatic lymphoepithelioma-like carcinoma response favorably to lenvatinib plus toripalimab.

Authors:  Yueting Zhu; Zhuyi Dang; Hang Xu; Yunlong Yuan; Ye Chen; Zhiping Li
Journal:  Cancer Sci       Date:  2022-03-24       Impact factor: 6.518

6.  Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report.

Authors:  Zhi-Xin Qiu; Ping Zhou; Ke Wang
Journal:  Onco Targets Ther       Date:  2019-10-17       Impact factor: 4.147

7.  Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Kai Yin; Hui-Bo Feng; Lin-Lin Li; Yu Chen; Zhi Xie; Zhi-Yi Lv; Wei-Bang Guo; Dan-Xia Lu; Xue-Ning Yang; Wen-Qing Yan; Yi-Long Wu; Xu-Chao Zhang
Journal:  Thorac Cancer       Date:  2019-12-03       Impact factor: 3.500

8.  The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: A systematic review and meta-analysis.

Authors:  Liansha Tang; Nan Chen; Wenbo He; Jian Zhou; Jinjue Zhang; Zhangyu Lin; Zihuai Wang; Jianqi Hao; Feng Lin
Journal:  PLoS One       Date:  2020-10-16       Impact factor: 3.240

9.  Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).

Authors:  Francesco Gelsomino; Giuseppe Lamberti; Marcello Tiseo; Danilo Rocco; Giulia Pasello; Fabiana Letizia Cecere; Antonio Chella; Giada Grilli; Marcella Mandruzzato; Michele Tognetto; Marina Chiara Garassino; Marianna Macerelli; Silvia Novello; Fausto Roila; Ida Colantonio; Francesco Grossi; Michelangelo Fiorentino; Andrea Ardizzoni
Journal:  Ther Adv Med Oncol       Date:  2020-07-20       Impact factor: 8.168

10.  Primary pulmonary lymphoepithelioma-like carcinoma: a rare type of lung cancer with a favorable outcome in comparison to squamous carcinoma.

Authors:  Bojiang Chen; Xuping Chen; Ping Zhou; Lan Yang; Jing Ren; Xiaodong Yang; Weimin Li
Journal:  Respir Res       Date:  2019-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.